Johnson & Johnson (JNJ)
156.76
-1.42
(-0.90%)
USD |
NYSE |
Mar 18, 16:00
156.81
+0.05
(+0.03%)
Pre-Market: 20:00
Johnson & Johnson Enterprise Value: 384.00B for March 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 18, 2024 | 384.00B |
March 15, 2024 | 387.42B |
March 14, 2024 | 389.90B |
March 13, 2024 | 394.46B |
March 12, 2024 | 398.41B |
March 11, 2024 | 394.77B |
March 08, 2024 | 390.65B |
March 07, 2024 | 389.09B |
March 06, 2024 | 390.22B |
March 05, 2024 | 391.74B |
March 04, 2024 | 391.42B |
March 01, 2024 | 396.91B |
February 29, 2024 | 395.13B |
February 28, 2024 | 395.54B |
February 27, 2024 | 394.17B |
February 26, 2024 | 393.71B |
February 23, 2024 | 396.24B |
February 22, 2024 | 392.89B |
February 21, 2024 | 388.63B |
February 20, 2024 | 386.65B |
February 16, 2024 | 383.50B |
February 15, 2024 | 386.80B |
February 14, 2024 | 381.55B |
February 13, 2024 | 383.30B |
February 12, 2024 | 386.63B |
Date | Value |
---|---|
February 09, 2024 | 384.00B |
February 08, 2024 | 382.87B |
February 07, 2024 | 386.68B |
February 06, 2024 | 386.87B |
February 05, 2024 | 381.43B |
February 02, 2024 | 383.38B |
February 01, 2024 | 387.59B |
January 31, 2024 | 388.89B |
January 30, 2024 | 388.58B |
January 29, 2024 | 390.00B |
January 26, 2024 | 390.33B |
January 25, 2024 | 390.48B |
January 24, 2024 | 389.03B |
January 23, 2024 | 391.08B |
January 22, 2024 | 397.48B |
January 19, 2024 | 395.58B |
January 18, 2024 | 394.45B |
January 17, 2024 | 392.57B |
January 16, 2024 | 392.79B |
January 12, 2024 | 397.29B |
January 11, 2024 | 394.31B |
January 10, 2024 | 396.04B |
January 09, 2024 | 395.46B |
January 08, 2024 | 395.22B |
January 05, 2024 | 394.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
301.41B
Minimum
Mar 23 2020
492.23B
Maximum
Apr 25 2022
417.62B
Average
421.83B
Median
Enterprise Value Benchmarks
Amgen Inc | 198.85B |
Gilead Sciences Inc | 108.90B |
Eli Lilly and Co | 747.04B |
Merck & Co Inc | 335.58B |
Moderna Inc | 31.23B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 4.049B |
Revenue (Quarterly) | 21.40B |
Total Expenses (Quarterly) | 17.09B |
EPS Diluted (Quarterly) | -0.03 |
Gross Profit Margin (Quarterly) | 68.23% |
Profit Margin (Quarterly) | 18.92% |
Earnings Yield | 7.73% |
Operating Earnings Yield | 6.00% |
Normalized Earnings Yield | 5.239 |